← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
126	GRCL 126 DELISTED Gracell Biotechnologies Inc. American Depositary Shares GRCL	–	–	–	–
127	GRML 127 Greenland Mines Ltd GRML $92.9M	–	–	–	–
128	GTH 128 DELISTED Genetron Holdings Limited ADS GTH	–	–	–	–
129	129 Fractyl Health GUTS $55.2M	–	–	–	–
130	130 Franklin Genomic Advancements ETF HELX $29.8M	–	–	–	–
131	131 iShares Genomics Immunology and Healthcare ETF IDNA $317M	–	–	–	–
132	132 Immix Biopharma IMMX $720M	–	–	–	–
133	133 Immatics IMTX $1.09B	–	–	–	–
134	134 IN8bio INAB $11.7M	–	–	–	–
135	135 MiNK Therapeutics INKT $50.7M	–	–	–	–
136	136 INmune Bio INMB $45.8M	–	–	–	–
137	137 Century Therapeutics IPSC $272M	–	–	–	–
138	KRBP 138 DELISTED Kiromic BioPharma, Inc. Common Stock KRBP	–	–	–	–
139	139 Korro Bio KRRO $137M	–	–	–	–
140	140 Krystal Biotech KRYS $9.77B	–	–	–	–
141	141 Kyverna Therapeutics KYTX $369M	–	–	–	–
142	142 Legend Biotech LEGN $3.85B	–	–	–	–
143	LGVN 143 Longeveron LGVN $4.78M	–	–	–	–
144	144 Lunai Bioworks LNAI $3.74M	–	–	–	–
145	LOGC 145 DELISTED LogicBio Therapeutics, Inc. Common Stock LOGC	–	–	–	–
146	146 Lexeo Therapeutics LXEO $227M	–	–	–	–
147	147 Lyell Immunopharma LYEL $201M	–	–	–	–
148	148 Mustang Bio MBIO $2.8M	–	–	–	–
149	149 DELISTED 23andMe Holding Co ME	–	–	–	–
150	150 MeiraGTx Holdings MGTX $950M	–	–	–	–